L-ARGININE REDUCES LIPID-PEROXIDATION IN PATIENTS WITH DIABETES-MELLITUS

Citation
B. Lubec et al., L-ARGININE REDUCES LIPID-PEROXIDATION IN PATIENTS WITH DIABETES-MELLITUS, Free radical biology & medicine, 22(1-2), 1997, pp. 355-357
Citations number
11
Categorie Soggetti
Biology
ISSN journal
08915849
Volume
22
Issue
1-2
Year of publication
1997
Pages
355 - 357
Database
ISI
SICI code
0891-5849(1997)22:1-2<355:LRLIPW>2.0.ZU;2-5
Abstract
A current concept for the development of diabetic long-term complicati ons is the involvement of oxidative stress, as, e.g., lipid peroxidati on, in the diabetic state. Data published recently show also oxidative damage to DNA, which might be one factor for accelerated aging and di abetic microangiopathy. In our study we tested the hypothesis that L-a rginine can reduce lipid peroxidation in patients with diabetes. We pe rformed a blind placebo controlled study with crossing over two treatm ent periods for 3 months. Thirty patients with diabetes mellitus were randomly assigned to treatment group A (first treatment then placebo) and B (first placebo then treatment). Treatment consisted of two daily dosages of 1 g L-arginine free base. Lipid peroxidation as reflected by malondialdehyde was evaluated in urine using a standard HPLC assay. After 3 months of treatment there was a significant reduction in malo ndialdehyde levels in group A (p < .0032), whereas there was no differ ence compared to the baseline values after three months of placebo tre atment in group B (p < .97). After crossing over, there was a signific ant reduction in malondialdehyde levels in group B (p < .0002). Group A showed a significant increase in malondialdehyde levels (p < .0063) returning to baseline values. L-Arginine treatment was able to reduce the lipid peroxidation product malondialdehyde. This provides evidence that treatment with L-arginine may counteract lipid peroxidation and thus reduce microangiopathic long-term complications in diabetes melli tus. Copyright (C) 1996 Elsevier Science Inc.